Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
RedHill Biopharma history
RedHill Biopharma company history timeline
In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million.
Following these preclinical studies, in June 2013, the company initiated a Phase IIa proof-of-concept study with RHB-104 for relapsing-remitting multiple sclerosis (“RRMS”) (the “CEASE MS” study) at two clinical sites in Israel.
In March 2014, the company entered into a License Agreement with Temple University to secure direct rights to patents related to the CDT® platform.
TALICIA® was granted Qualified Infectious Disease Product (“QIDP”) designation by the FDA in November 2014.
Salix (now Valeant), which acquired a worldwide exclusive license to RHB-106 and other purgative developments from it, estimated in its 2014 Investor Day that the peak year revenue from their encapsulated bowel prep would reach approximately $280 million.
Xifaxan® is an antibiotic treatment that was approved for the treatment of IBS-D in 2015.
In October 2016 the company reported the results from the MAP diagnostic development program, including an initial validation of its platform PCR (polymerase chain reaction) detection methodology licensed from UCF and developed by Professor Saleh A. Naser.
At the first DSMB meeting, held in December 2016, safety data from the study was reviewed.
According to Ryu YJ et al. (Tuberc Respir Dis, 2016) the incidence and prevalence of NTM lung disease are increasing worldwide, while treatment options remain limited, lengthy and challenging.
The total worldwide sales of multiple myeloma therapies were estimated to exceed $18 billion in 2018 according to GlobalData.
The report also estimated that the sales of therapies for Crohn’s disease in these territories would exceed $12 billion in 2022.
Rate how well RedHill Biopharma lives up to its initial vision.
RedHill Biopharma jobs
Do you work at RedHill Biopharma?
Is RedHill Biopharma's vision a big part of strategic planning?
RedHill Biopharma history FAQs
Zippia gives an in-depth look into the details of RedHill Biopharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about RedHill Biopharma. The employee data is based on information from people who have self-reported their past or current employments at RedHill Biopharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by RedHill Biopharma. The data presented on this page does not represent the view of RedHill Biopharma and its employees or that of Zippia.
RedHill Biopharma may also be known as or be related to REDHILL BIOPHARMA LTD, RedHill Biopharma, RedHill Biopharma Ltd, RedHill Biopharma Ltd. and Redhill Biopharma Ltd.